Details of a Researcher - AKAMINE Yumiko

PURPOSE: The effects of polymorphisms in CYP3A4, UGT2B7, ABCB1, ABCG2, ABCC2, NR1I2, and AHR genes on asciminib exposure were evaluated in Japanese patients with chronic myeloid leukemia. METHODS: Plasma concentrations of asciminib (40 mg twice daily [BID] or 80 mg once daily [QD]) were measured by high-performance liquid chromatography. Statistical analysis was performed using SPSS (P < 0.05). RESULTS: For both regimens, the median asciminib area under the concentration-time curve (AUC) was significantly higher in female than in male patients (P = 0.009 and 0.004, respectively). Significant correlations were observed between the asciminib AUC of 40 mg BID or 80 mg QD and body weight (P = 0.042 and < 0.001, respectively). The asciminib AUC0-12 of 40 mg BID in patients with the -25385 T allele of the NR1I2 -25385C > T polymorphism was significantly lower than that in patients with the -25385C/C genotype (5363 and 10607 ng∙h/mL, respectively, P = 0.001). In multiple regression analyses, the NR1I2 -25385C > T polymorphism (P = 0.001) and female sex (P = 0.002) were independently predictive of a higher asciminib AUC0-12 for the 40 mg BID regimen (determination coefficient: 52.8%), whereas body weight (P < 0.001) and female sex (P = 0.047) were independently predictive of a higher asciminib AUC0-24 for the 80 mg QD regimen (determination coefficient: 52.2%). CONCLUSION: Overall, our findings showed that an adjustment of the initial asciminib dose may be needed based on genotyping information for the NR1I2 -25385C > T polymorphism and the body weight of the patient; however, further prospective studies are necessary.

DOI PubMed

Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer.

Hayato Yokota, Satoshi Goshima, Yuji Okuda, Sho Sakamoto, Masahide Takeda, Kazuhiro Sato, Yumiko Akamine, Katsutoshi Nakayama, Masatomo Miura

Case reports in oncological medicine 2026 7788444 - 7788444 2026

Research paper (journal)

INTRODUCTION: Erlotinib (ERL) is metabolized primarily by cytochrome P450 (CYP) 3A4. We report a case of non-small cell lung cancer in which plasma ERL concentrations increased following coadministration of itraconazole (ITCZ). CASE PRESENTATION: In this patient, a 67-year-old man receiving ERL 150 mg/day, the trough plasma concentration (C 0) of ERL and its major metabolite, O-desmethyl ERL (OSI-420), increased following coadministration of ITCZ. The total clearance of ERL at steady state was 6.1 L/h. The mean C 0 of ERL and OSI-420 were 437 and 47.1 ng/mL, respectively, and the C 0 ratio of OSI-420/ERL was 0.108. With coadministration of oral ITCZ (200 mg/day capsule), the mean C 0 of ERL and OSI-420 increased to 1124 and 166 ng/mL, respectively, and the mean C 0 ratio of OSI-420/ERL increased to 0.147. The mean C 0 of ITCZ and the sum of ITCZ and the active metabolite hydroxyitraconazole (OH-ITCZ) were 109 and 271 ng/mL, respectively. The mean C 0 of ERL increased approximately 2.5-fold. CONCLUSION: Even at the relatively lower C 0 of ITCZ (compared with the recommended target value), ITCZ coadministration increased the C 0 of ERL. In patients with a sufficient ERL C 0 of more than 500 ng/mL prior to ITCZ coadministration or patients exhibiting adequate absorption of oral ITCZ, the risk of ERL-related adverse events with ITCZ coadministration may increase due to further elevation of the ERL C 0. Therefore, when ERL is coadministered with ITCZ, careful monitoring for adverse effects and appropriate dose adjustments are required, considering potential changes in ERL concentrations. Management using the C 0 of ERL and ITCZ may be necessary.

DOI PubMed

Efficacy of Switching to Levetiracetam After S-1-Induced Phenytoin Concentration Increase: A Case Report.

Hayato Yokota, Haruka Igarashi, Yumiko Akamine, Shinichiro Atsumi, Akise Umakoshi, Masafumi Kikuchi

Cureus 17 ( 4 ) e82653 2025.04

Research paper (journal)

S-1, an oral anticancer drug, interacts with phenytoin (PHT) to increase PHT serum concentration. Although the PHT dosage is usually adjusted, few studies have examined the effects of switching from PHT to another antiepileptic drug. Here, we report the details of a case in which a patient with gastric cancer continued adjuvant chemotherapy after switching from PHT to levetiracetam (LEV) to prevent interactions with S-1. A man in his 60s with advanced gastric cancer received adjuvant chemotherapy with S-1 120 mg/day (cycles of two weeks of administration followed by one week of rest). He had experienced generalized tonic-clonic seizures 48 years prior and had been taking PHT (170 mg/day) and carbamazepine (250 mg/day). On day 22 of treatment, the PHT concentration increased from 3.72 to 11.76 µg/mL. On day 25, he developed dizziness and fell. Gradual PHT dose reduction and a switch to LEV improved his symptoms, and he remained seizure-free over nine treatment cycles. The findings of this case report suggest an approach for switching from PHT to another antiepileptic drug when PHT levels increase due to interactions with S-1. Switching to LEV may result in fewer interactions.

DOI PubMed

Comparison of Serum Vancomycin Concentrations using a New Automated Analyzer based on High-Performance Liquid Chromatography and Chemiluminescent Immunoassay

Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ( Japanese Society of Pharmaceutical Health Care and Sciences ) 51 ( 4 ) 187 - 195 2025.04

Research paper (journal)

DOI CiNii Research

display all >>

To the head of this page.▲